SMARCA1 and pancreatic neoplasm: Importantly, our SWI/SNF-altered pancreatic cancer group not receiving immunotherapy similarly did not have a KRAS mutation in 2 of 5 (40%) patients with available data, underscoring the likely genomic relevance of SWI/SNF complex members in pancreatic cancer carcinogenesis.